#API Manufacturing Industry

[andy1199posts]

API Manufacturing: Global Opportunities & Forthcoming Trends

Global Growth Driving Factors:Some of the key factors propelling this market’s growth are the expansion of production capacity by biopharmaceutical and pharmaceutical companies, the increasing significance of generics, and technological developments in API manufacturing. However, it is anticipated that in the upcoming years, the market for active pharmaceutical ingredients will be restrained by…

[chemxpert]

Why is Data Critical in Life Sciences and the Emerging Trends in 2024

The life  sciences industry covers sectors such as pharmaceuticals, biotechnology, healthcare, and medical devices, and the sector has been rapidly evolving in the last few years based on the interaction of  data analytics, AI, and other corresponding digital technologies. The growth of precision medicine, a desire for better efficiency in drug development, and a growing focus on patient outcomes are part of the reason why data has become so critical to innovation in the life sciences industry today.

[octanexlabsin]

Shaping the Future of Chemical Synthesis: Dedicated to Pharma, Agro, Fine and Specialty Chemicals, CRO, and CDMO sectors, we deliver advanced synthesis solutions with a strong emphasis on quality. Through custom development and CRAMS, we collaborate with global clients to meet the highest standards. Our purpose is to improve life quality through outstanding research, manufacturing, and marketing efforts.

[asymchem1]

Carbapenems Manufacturing | Pharma API and Raw Materials by Asymchem

Asymchem specializes in Carbapenems and pharma API manufacturing, providing high-quality raw materials for the pharmaceutical industry. Partner with us for reliable solutions.

[market-insider]

ontract Manufacturing in the Generic Pharma Sector: Trends and Analysis

The global generic pharmaceuticals contract manufacturing market size is expected to reach USD 106.9 billion by 2030, registering a CAGR of 5.8% over the forecast period, according to a new report by Grand View Research, Inc. Cost-saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving the industry. A significant number of people globally suffer from chronic diseases. For instance, the CDC states that 6 in 10 adults in the U.S. suffer from at least one chronic disease and 4 in 10 adults suffer from two or more chronic diseases. Chronic diseases are required to be treated for a long time. The high cost of medicines is increasing the demand for cost-effective generic drugs for the treatment of chronic diseases.

Generic Pharmaceuticals Contract Manufacturing Market Report Highlights

The branded generics segment held the largest share in 2021due to the preference for branded generics among physicians. Some branded generic manufacturers offer benefits and gifts to physicians for boosting their product sales. This further contributes to the demand for branded generic manufacturing in the market

The API product segment held the largest share in 2021. The growing demand for generic drugs is supporting the demand for generic API contract manufacturing

The parenteral route of administration segment is expected to grow at the fastest CAGR over the forecast period due to the bioavailability of parenteral drugs over other formulations

The oncology segment is expected to register the fastest CAGRfrom 2022 to 2030 owing to the high cost of cancer drugs contributing to the demand for cost-effective generic medicines

Asia Pacific is expected to record the highest CAGR over the forecast period mainly due to the low cost of generic drug manufacturing

Gain deeper insights on the market and receive your free copy with TOC now @: Generic Pharmaceuticals Contract Manufacturing Market Report

This is expected to support the industry's growth post-pandemic. There is an improvement in the regulatory approval of generic drugs. For instance, in 2021, the FDA approved 93 generic drugs, and by October 2022, the regulatory authority approved over 95 generic drugs. Such improvements are expected to have a positive impact on the manufacturing of generic drugs and; thus, support the industry growth. The Japanese government is constantly trying to improve the generic pharmaceuticals market in the country. The government is also taking measures to improve the supply of generics in the country and is also encouraging medical institutes to promote the use of generic drugs.

This is expected to improve CMO activities for generics in the coming years. Global spending on medicines is also on the rise. According to the data provided in a report published by IQVIA in April 2021, global spending on medicine is expected to increase in the next 4-5 years. The report states that global spending on medicine accounted for USD 1, 265 billion in 2020 and is going to reach USD 1,580-1,610 billion by 2025. This is also expected to improve the demand for generic drugs owing to their cost efficiency, thereby supporting the industry in growth.

[neha24blog]

High Potency API Contract Manufacturing Market Outlook On The Basis Of Product Type, Application, Synthesis, Dosage Form, Region And Forecast to 2030: Grand View Research Inc.

San Francisco, 10 Aug 2023: The Report High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Innovative, Generic), By Dosage Form (Injectable, Creams), By Application, By Synthesis, And Segment Forecasts, 2022 – 2030 The global high potency API contract manufacturing market size is expected to reach USD 14.65 billion by 2030, registering a CAGR of…

[cheminopharma]

Chemino Pharma was founded in 2001, with the aim of being the “most preferred supply partner” in the Pharmaceutical and Solvents segments. Manufacturing of API(Human), API(Veterinary) and Intermediate Chemicals. Dedicated division for trading in chemical solvents. We are Lead Manufacturer for fenbendazole API manufacturers in India, and Expert API manufacturers of citicoline sodium.

Gmail: enquiry@cheminopharma.com ; Phone : +91 86 89 89 73 73

[justinspoliticalcorner]

Lori Ann Larocco at CNBC:

Billions in trade came to a screeching halt at U.S. East Coast and Gulf Coast ports after members of the International Longshoremen’s Association (ILA) began walking off the job after 12:01 a.m. ET on October 1. The ILA is North America’s largest longshoremen’s union, with roughly 50,000 of its 85,000 members making good on the threat to strike at 14 major ports subject to a just-expired master contract with the United States Maritime Alliance (USMX), and picketing workers beginning to appear at ports. The union and port ownership group failed to reach agreement by midnight on a new contract in a protracted battle over wage increases and use of automation. In a last-ditch effort on Monday to avert a strike that will cause significant harm to the U.S. economy if it is lengthy — at least hundreds of millions of dollars a day at the largest ports like New York/New Jersey — the USMX offered a nearly 50% wage hike over six years, but that was rejected by the ILA, according to a source close to the negotiations. The port ownership group said it hoped the offer would lead to a resumption of collective bargaining.

The 14 ports where preparations for a strike have been underway are Boston, New York/New Jersey, Philadelphia, Wilmington, North Carolina, Baltimore, Norfolk, Charleston, Savannah, Jacksonville, Tampa, Miami, New Orleans, Mobile, and Houston. New York Governor Kathy Hochul said in a statement issued shortly after midnight that “the first large-scale eastern dockworker strike in 47 years began at ports from Maine to Texas, including at the Port Authority of New York and New Jersey. In preparation for this moment, New York has been working around the clock to ensure that our grocery stores and medical facilities have the essential products they need.” Rhetoric from ILA leadership has been aggressive in the weeks leading up to the strike, with ILA president Harold Daggett, who was a union member the last time it went out on strike in 1977, telling rank-and-file members — who unanimously voted to authorize a strike — in a recent video message, “We’ll crush them.” 

[...] The most significant issues would be faced by food and automobile industries, Kamins said, as they rely especially heavily on the ports that will be shut down. While a surge in inflation is highly unlikely even with a longer strike, even a modest reacceleration could create uncertainty and force the Federal Reserve to be more cautious about lowering interest rates, which would weigh on the overall outlook for job growth and investment. A one-week strike could cost the U.S. economy $3.78 billion, according to an analysis by The Conference Board, and cause supply chain slowdowns through mid-November. In all, the ports threatened with strikes handle $3 trillion annually in U.S. annual international trade.

Many industries are preparing for major repercussions. Noushin Shamsili, CEO and president of Nuco Logistics, which specializes in pharmaceutical imports and exports, said the strike comes at a critical time for inventory replenishment for the pharma sector. “Almost all of this industry is just on time,” said Shamsili. “Raw materials are being brought in to complete drug manufacturing. Medical supplies for clinics and hospitals are on these vessels. For a while importers did not bring in a lot of cargo because they were overflowing with supplies post-Covid. Now they have started reordering medical devices, gloves, syringes, and tubing.” Shamsili also said the East Coast ports are a gateway for generic medicine made in India. Approximately 48% of the active pharmaceutical ingredients used in the U.S. are being imported from India. Without these APIs, medications cannot be produced. APIs are also manufactured in Europe, which also use the East Coast ports as U.S. points of entry.

[...] The Biden administration finds itself in a delicate political moment, with the presidential election one month away and President Biden vowing he will not use existing labor law to force union workers back on the job, which is within his powers under the Taft-Hartley Act. The Taft-Hartley Act, passed in 1947, was a revision of U.S. law governing labor relations and union activity that granted a U.S. president the power to suspend a strike for an 80-day “cooling off period” in cases where “national health or safety” are at risk. 

Today begins the strike along East Coast and Gulf Coast ports after International Longshoremen’s Association (ILA) members walked off their jobs.

This strike, depending on how long it lasts, could have a major impact on the elections and the economy.

[rjzimmerman]

Excerpt from this story from The American Prospect:

The Clean Air Act (CAA) has been fiercely opposed by polluters and their allies since its passage in 1970. Industry has never quite stopped fighting to prevent the government from protecting American lives and communities at the expense of even a bit of their profits. But over the past few years, opposition to the law has reached new feverish heights. Multiple cases seeking to gut the CAA have been filed by (or with the support of) oil and gas organizations, their dark-money front groups, and their political allies since 2022.

The ringleaders of this effort are the usual trade groups driving climate apocalypse, including the American Fuel and Petrochemical Manufacturers (AFPM) and the American Petroleum Institute (API), as well as oil giants themselves, like ExxonMobil.

Yet the coordinated attacks on this lifesaving, popular, and historically successful regulation go beyond the singularly destructive interests of the oil industry alone. And they go beyond the federal rule too, and are working their way into litigation against state enactments of the CAA.

Of course, many of the companies driving these suits are some of the biggest names in corporate greenwashing, like Amazon, FedEx, SoCalGas, and more.

These companies have continuously insisted that they are committed to leading the clean-energy transition, even while they fight for the right to poison the general public for profit, and have endeavored—at every turn—to destroy any opportunity the public may have to pursue recourse for it.

Last year, the Truck and Engine Manufacturers Association (EMA) threatened a lawsuit against the California Air Resources Board (CARB) over the state regulator’s Advanced Clean Fleets (ACF) rule.

The rule, which would mandate a “phased-in transition toward zero-emission medium- and heavy-duty vehicles,” threatens the transportation sector’s historically noxious way of doing business; the sector accounts for more than 35 percent of California’s nitrogen oxide emissions and nearly a quarter of California’s on-road greenhouse gas emissions. CARB’s rule could go a long way toward actualizing rapid reductions in the state’s annually generated emissions.

However, later that year EMA and some major truck manufacturers reached an agreement with CARB not to sue over the rules, in exchange for the state’s loosening of some near-term emissions reductions standards.

EMA has by and large kept its promise to not intervene with the regulation in courts, but litigation challenging CARB’s rule would soon be picked up by the California Trucking Association (CTA). Enforcement of the rule has since been on hold, as CARB waits to be issued an ACF-related waiver from the EPA in return for CTA not filing for preliminary injunction against the law.

Even despite these agreements, some of EMA’s own members—and even some of those specifically signed on to the CARB deal—pop up on CTA’s member rolls, as per CTA’s own 2023 membership directory. Daimler Trucks North America and Navistar, Inc., are specifically listed as Allied Members of CTA for 2023.

Amazon is listed among CTA’s Carrier Members, while separately making routine promises to be a partner in the fight against climate change. While Amazon announced its “Climate Pledge” in 2019 of reaching net-zero emissions by 2040 to great fanfare, and has since branded itself a climate leader, the Center for Investigative Reporting has detailed how the e-commerce giant is overselling its green credentials by drastically undercounting its carbon emissions.

In truth, Amazon’s emissions have increased more than 40 percent in the time since it issued the pledge. Amazon also remains the largest emitter of the “Big Five” tech companies, producing no less than 16.2 million metric tons of CO2 every year. Without question, the corporation should be regarded as an industry leader in greenwashing, rather than in actual climate action.

FedEx is also a CTA Carrier-level member. Like Amazon, the company has also made promises “to achieve carbon neutral operations by 2040,” an initiative FedEx has labeled “Priority Earth.” In the years since, FedEx has funneled intensive time and resources into lobbying directly against climate action while pushing its net-zero greenwashing narrative.

UPS is another CTA Carrier-level member. UPS has historically been less effusive in its climate promises than have other corporations on this list, but the delivery giant has continuously reinforced its stance that “everyone shares responsibility to improve energy efficiency and to reduce GHG emissions in the atmosphere.”

[pharmaapimanufacturer]

Explore Dr. Reddy's cutting-edge manufacturing capabilities, leveraging advanced technologies and industry expertise. Discover our commitment to quality, innovation, and global pharmaceutical leadership.

[andy1199posts]

Exploring the Growing Market for Active Pharmaceutical Ingredients

What are Active Pharmaceutical Ingredients? Active Pharmaceutical Ingredients (APIs) are the active ingredients in a drug that are responsible for its therapeutic effects. They are typically synthesized in a laboratory and are used in the formulation of medicines, including tablets, capsules, injectables, ointments and other topical preparations. Introduction to the Global API Industry: The…

[chemxpert]

How India Ranked in The Global Pharma Market in 2024

India’s pharmaceutical industry has been a cornerstone of the global healthcare landscape for decades. In 2024, the country reaffirmed its status as a major player in the global pharma market, capitalizing on its robust infrastructure, skilled workforce, and cost-effective production capabilities. This blog delves into India’s current standing in the pharmaceutical sector, the driving forces behind its growth, and the challenges it faces.

[steelindustryman]

Discover the Strength and Versatility of GI Flange

Q1: What are the key processes involved in the manufacture of GI flanges?

A: The key processes in the manufacture of GI flanges include:

Material Preparation: Raw materials like steel plates or sheets are cut to size.

Forming: The material is shaped into the flange design using processes like stamping or forging.

Welding: If needed, flanges may be welded to create specific designs.

Galvanization: The flanges are coated with zinc through hot-dip galvanization or electro-galvanization to enhance corrosion resistance.

Finishing: Final finishing processes include cleaning, inspection, and surface treatment to ensure quality.

Q2: Which materials are typically used in the production of GI flanges?

A: The primary material used in the production of GI flanges is carbon steel, which is coated with zinc to provide corrosion resistance. Depending on specific requirements, other materials such as stainless steel may also be used.

Q3: How do manufacturing standards affect the quality of GI flanges?

A: Manufacturing standards, such as ASTM, ANSI, and ISO, provide guidelines for the design, material specifications, and testing of GI flanges. Adhering to these standards ensures consistency, reliability, and safety in the final product, significantly affecting its overall quality.

Q4: What industries commonly utilize GI flanges?

A: GI flanges are commonly used in various industries, including:

Construction

Oil and gas

Water and wastewater treatment

HVAC (Heating, Ventilation, and Air Conditioning)

Shipbuilding

Q5: Can you customize GI flanges according to specific project requirements?

A: Yes, GI flanges can be customized based on specific project requirements, including size, thickness, pressure rating, and design specifications, to meet the needs of different applications.

Q6: What certifications should a manufacturer of GI flanges have?

A: A manufacturer of GI flanges should ideally have certifications such as:

ISO 9001 (Quality Management System)

ISO 14001 (Environmental Management)

API (American Petroleum Institute) certifications for oil and gas applications

Other industry-specific certifications as required.

Q7: How does the manufacturing process ensure corrosion resistance in GI flanges?

A: Corrosion resistance is ensured through the galvanization process, where flanges are coated with zinc, which serves as a sacrificial anode. This protects the underlying steel from rust and corrosion when exposed to moisture and other corrosive elements.

Q8: What are the advantages of using GI flanges over other types of flanges?

A: The advantages of using GI flanges include:

Cost-Effectiveness: Generally less expensive than stainless steel flanges.

Corrosion Resistance: The zinc coating provides excellent protection against rust.

Versatility: Suitable for a wide range of applications and environments.

Strength and Durability: Good mechanical properties make them reliable under pressure.

Q9: How does the cost of manufacturing GI flanges compare to other flange types?

A: The cost of manufacturing GI flanges is typically lower than that of stainless steel or other specialty flanges, primarily due to the lower cost of raw materials and the manufacturing processes involved.

Q10: What quality control measures are in place during the manufacture of GI flanges?

A: Quality control measures during the manufacture of GI flanges may include:

Regular inspections and testing of raw materials.

In-process inspections to ensure dimensional accuracy and adherence to specifications.

Testing for corrosion resistance, mechanical strength, and other relevant properties.

Final product inspections before shipment to ensure compliance with standards and customer specifications.

[soniez]

India's Pharma Industry – The Leading Companies You Need to Know

India's pharmaceutical industry stands as a global powerhouse, contributing significantly to the world's supply of medicines and pharmaceutical products.  The country's ability to produce high-quality, affordable medicines has earned it the title of "Pharmacy of the World."  As the industry continues to grow and innovate, several companies have emerged as leaders in the market.  For Centurion HealthCare Pvt. Ltd., understanding the landscape of the top pharma companies in India provides insights into the key players driving the industry's success.

The Rise of the Pharmaceutical Industry in India

The pharmaceutical industry in India has seen exponential growth over the past few decades.  From generic drug manufacturing to complex biotechnological innovations, Indian pharma companies have made substantial contributions to global healthcare.  This growth can be attributed to several factors, including a skilled workforce, robust research and development infrastructure, and supportive government policies.

Key Players in India's Pharma Industry

The landscape of the pharmaceutical industry in India is populated by numerous companies, each contributing to various segments of the market.  Here are some of the top pharmaceutical companies in India that are leading the charge:

1.   Sun Pharmaceutical Industries Ltd.

As the largest pharmaceutical company in India, Sun Pharma is renowned for its diverse product portfolio, including generics, branded generics, specialty medicines, and active pharmaceutical ingredients (APIs).  The company has a significant global presence and continues to expand its footprint through strategic acquisitions and partnerships.

2.   Dr. Reddy's Laboratories

Dr. Reddy's is a major player in the global generic pharmaceutical market.  Known for its strong focus on research and development, the company offers a wide range of pharmaceuticals and biotechnology products.  Their commitment to quality and innovation has solidified their position as one of the best pharmaceutical companies in India.

3.   Cipla Ltd.

Cipla has been at the forefront of providing affordable medicines for over eight decades.  The company specializes in respiratory, cardiovascular, anti-retroviral, and anti-infective therapies.  Cipla's dedication to healthcare accessibility and its significant contributions to global health initiatives make it a top pharmaceutical company in India.

4.   Lupin Limited

Lupin is a leading pharmaceutical company known for its focus on complex generics and specialty drugs.  The company's strong presence in both developed and emerging markets has earned it a place among the top 10 pharmaceutical companies in India.  Lupin's investment in R&D and its broad therapeutic portfolio are key drivers of its success.

5.   Aurobindo Pharma

Aurobindo Pharma is recognized for its extensive range of generic formulations and APIs.  The company's robust manufacturing capabilities and strategic global presence have made it one of the top pharmaceutical companies in India.  Aurobindo's commitment to innovation and quality continues to propel its growth.

6.   Zydus Cadila

Zydus Cadila, a leading pharmaceutical company, offers a wide range of healthcare solutions, including small molecules, biologics, biosimilars, and vaccines.  The company's integrated operations and strong research capabilities have established it as a key player in the pharma industry in India.

7.   Glenmark Pharmaceuticals

Glenmark is a global research-led pharmaceutical company known for its focus on innovation in the fields of dermatology, respiratory, and oncology.  The company's strong pipeline of new chemical entities and biosimilars underscores its position as one of the best pharmaceutical companies in India.

8.   Torrent Pharmaceuticals

Torrent Pharma is a major player in the cardiovascular and central nervous system therapeutic areas.  The company's strategic acquisitions and focus on niche segments have helped it become one of the top pharmaceutical companies in India.  Torrent's commitment to quality and patient-centric approach is evident in its product offerings.

9.   Biocon Ltd.

Biocon is India's largest biopharmaceutical company, specializing in biologics and biosimilars.  The company's focus on affordable innovation and its significant contributions to chronic disease management make it a leader in the pharmaceutical industry in India.  Biocon's global partnerships and strong R&D capabilities are key to its success.

10. Cadila Healthcare (Zydus)

Cadila Healthcare, also known as Zydus, is a prominent player in the Indian pharma industry, offering a wide range of healthcare solutions.  The company's innovative approach and comprehensive product portfolio have positioned it among the top 10 pharmaceutical companies in India.

The Role of Pharma Manufacturing Companies in India

Pharma manufacturing companies in India play a crucial role in the global supply chain of medicines.  These companies not only produce high-quality generics but also invest heavily in research and development to bring new and innovative drugs to the market.  The efficiency and scale of Indian pharma manufacturing are key factors in the country's ability to provide affordable medicines worldwide.

Finding the Best Pharma Companies Near You

For those searching for "pharma companies near me," it's important to recognize the regional presence of leading pharmaceutical companies.  Many top pharma companies in India have established manufacturing and research facilities in various parts of the country, ensuring widespread access to their products and services.

Centurion HealthCare Pvt. Ltd.  – A Leading Player in the Industry

Centurion HealthCare Pvt. Ltd. is an emerging name in the Indian pharmaceutical landscape.  As a medicine manufacturing company in India, Centurion HealthCare is dedicated to providing high-quality pharmaceutical products across various therapeutic categories.  The company's commitment to innovation, quality, and patient care positions it among the best pharma companies in India.

The Future of the Pharmaceutical Industry in India

The future of the pharmaceutical industry in India looks promising, with continued growth driven by innovation, increasing healthcare needs, and expanding global reach.  Indian pharma companies are expected to play a pivotal role in addressing global health challenges, developing new treatments, and ensuring the availability of affordable medicines.

Conclusion

India's pharmaceutical industry is a dynamic and rapidly evolving sector, with numerous companies leading the way in innovation, quality, and global healthcare contributions.  From established giants like Sun Pharma and Dr. Reddy's to emerging leaders like Centurion HealthCare Pvt. Ltd., the top pharmaceutical companies in India are making significant strides in improving healthcare outcomes worldwide.

As the industry continues to grow, these companies will remain at the forefront of pharmaceutical advancements, ensuring that India retains its position as a global leader in medicine production and innovation.  Whether you are looking for the best pharma company in India or seeking reliable pharmaceutical companies in India, the landscape is rich with options that exemplify excellence and commitment to health.

For Centurion HealthCare Pvt. Ltd., being part of this esteemed group of pharma companies in India is a testament to its dedication to quality, innovation, and patient care.  As the industry moves forward, Centurion HealthCare is poised to continue its growth and contribute to the global healthcare landscape, solidifying its place among the best pharmaceutical companies in India.

[pharma-franchise01]

The Future Of Derma PCD Franchise Company In India: Trends and Opportunities

Dermatology is one of the major branches of medical science. Looking at the shining present and bright future of PCD Derma franchise company in India. Many pharma companies have started to own the Derma PCD franchise company in India. 

With the high rise in the API index in every city in India, we know that pollution is tempering our health inside out. From lung infection to skin diseases heavy pollution and unclean surroundings are common in all cities. Skin allergies, fungal infections, acne, pimples and dark spots are just a few consequences of living in a polluted environment. Unhygienic and unhealthy eating is also one of the main reasons for building skin-related issues. Tempering the food with artificial colouring and other agents leads to skin irritation and allergies for many people.  

People try to treat these problems by buying common derm products from any medical shop. And this panic buying resulted in high sales of derma products. Many entrepreneurs grabbing this opportunity and starting a derma franchise company in India.

The Present of a Derma Franchise Company in India

Nowadays people often see dermatologist doctors for the treatment of their skin-related ailments. Thus it increases the sale of dermatological products in the market, and with the high demand big opportunities start lining up. 

Several derma products are available in the market, most of them are prescription free and some have to be prescribed by the derma doctor because of their drug formulation. Combining both, derma products have a huge market in India. We know the obsession of Indians with skin care products.

Talking about the present for the derma franchise company in India it's bright and most pharma companies “operating in derma products“ are thriving. See around yourself and mind the shelves of medical shops, their display shelves are full of derma products. 

 The Future of a Derma Franchise Company in India

Right now, is the best time to own a derma franchise company in India. Many reputed PCD derma franchise companies in India are running with throttle to meet the market expectations, they are also supporting other pharma companies by providing their franchises of derma products.

From the distribution of franchises to third-party manufacturers all are sailing the boat without paddling. That is why the future of the derma market and derma franchises are even brighter minding the increment in skin-related issues. 

Rising opportunities with the expansion of the Derma market 

Capitalising on the Derma market expansion is the best option for finding an astounding and resilient Derma PCD franchise company in India. It is the right time to partner with the Derma PCD franchise company because they not only provide their franchise to compete in the Derma market but also provide tools to leverage the opportunity for breaking into the market. 

Derma PCD Franchise company in India provides its franchisee the right to market and distribute its product without any intervention. You may find the Medliva Franchise perfect for your company because they have a wide range of derma products.

This Derma franchisor can provide complete marketing and promotional support to franchisees. We have achieved heights in the pharma industry. Hence partnering and taking a derma franchise company in India could be a game-changing choice for your business growth.